Research progress of eicosanoid metabolomics in cardiovascular diseases.
- Author:
Qian-Kun BAO
1
;
Xu ZHANG
2
;
Yi ZHU
3
Author Information
1. Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Department of Cardiology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China.
2. Tianjin Key Laboratory of Metabolic Diseases, Key Laboratory of Immune Microenvironment and Disease-Ministry of Education, Department of Physiology and Pathophysiology, Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Medical University, Tianjin 300070, China.
3. Tianjin Key Laboratory of Metabolic Diseases, Key Laboratory of Immune Microenvironment and Disease-Ministry of Education, Department of Physiology and Pathophysiology, Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Medical University, Tianjin 300070, China. zhuyi@tmu.edu.cn.
- Publication Type:Review
- MeSH:
Arachidonic Acid;
Cardiovascular Diseases;
Cytochrome P-450 Enzyme System;
Eicosanoids;
Humans;
Metabolomics
- From:
Acta Physiologica Sinica
2021;73(4):606-616
- CountryChina
- Language:Chinese
-
Abstract:
Eicosanoids are oxidized derivatives of 20-carbon polyunsaturated fatty acids (PUFAs). In recent years, the role and mechanism of eicosanoids in cardiovascular diseases have attracted extensive attention. Substrate PUFAs including arachidonic acid are metabolized by cyclooxygenase, lipoxygenase, cytochrome P450 oxidase enzymes, or non-enzymatic auto-oxidation. Eicosanoid metabolomics is an effective approach to study the complex metabolic network of eicosanoids. In this review, we discussed the biosynthesis and functional activities of eicosanoids, the strategies of eicosanoid metabolomics, and applications and research progress of eicosanoid metabolomics in cardiovascular diseases, which might offer new insights and strategies for the treatment of cardiovascular diseases.
